Trial Profile
A Phase I, Randomized, Single Dose, Crossover Study Evaluating the Pharmacokinetics and Pharmacodynamics of Pegfilgrastim Hospira Compared to Neulasta (Amgen) Following Subcutaneous Administration to Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Pegfilgrastim (Primary)
- Indications Neutropenia
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Hospira
- 25 Mar 2014 New trial record